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Abstract  
Objective:  To determine the safety and efficacy of vaccinating the male gender to prevent HPV 
related neoplastic disorders in both the male and female genders.   
 
Study Design:  Review of all randomized controlled trials and comparative studies in the 
English language from the time periods of 2000 to 2009.  
 
Data Sources:  Two RCT’s and one comparative study was found using PubMed, Ovid, 
Cochrane database of Randomized Control Trials, and Cochrane database of Systematic 
Reviews.   
 
Outcomes Measured:  Outcomes were measured for safety and efficacy.  Outcomes were based 
upon a vaccination report card (VRC) and proven immunity to the HPV types being studied.  
Participants were given a scale and asked to rate their symptoms based upon mild, moderate, or 
severe.  “Mild” was defined as awareness of signs or symptoms, but easily tolerated; “moderate” 
was defined by discomfort enough to cause interference with usual activities; and “severe” was 
incapacitating with the inability to work or do usual activities (Block).
1 
 Titer levels were drawn 
to associate immunogenicity within the participants.  Numeric values of titer levels however are 
not POEM based.  What is POEM based is whether or not these patients will be able to know 
that they are protected from contracting or transmitting HPV 6/11/16/18 and related neoplasm’s.   
 
Results:  Two RCT’s and one comparative study were included in this review.  All three of the 
studies proved safety and efficacy of either the quadrivalent or bivalent HPV vaccine.  Very few 
serious adverse events (SAEs) were contributed to the vaccination.  Only 1 SAE was said to be 
vaccination related.  Immunogenicity was proved to be non-inferior to girls and women in all 3 
studies.    
 
Conclusions:  The Block study, the Petaja study, and the Reisinger study all show that the HPV 
vaccine is overall safe and effective for the male population.   
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Introduction 
Human Papillomavirus (HPV) infections are responsible for causing neoplasms in both 
the male and female genders.  There are more than 100 HPV viruses, and around 30 out of these 
100 are passed through sexual contact.  HPV infections are divided into two groups; low risk and 
high risk.    The low risk types are known to be HPV types 6 and 11; the high risk types are 
known to be HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 73.  The high risk 
category is known to be oncogenic or carcinogenic.  HPV infections are common with a lifetime 
risk exceeding 50% for both males and females.
3
  HPV is a major cause of cervical and 
anogenital cancers; therefore the high prevalence of genital HPV infection is considered a 
serious worldwide health issue.
3
  Due to the well-established link between HPV and anogenital 
cancers, genital warts, and low/high grade dysplasia, there is now a prophylactic vaccine 
available for the four most common types of low and high risk HPV.  The quadrivalent vaccine 
was approved in 2006 and first available only to females; this vaccine is now extended to males 
after FDA approval in October 2009.
6
    
Worldwide, greater than 500,000 cases of cervical and other genital cancers are caused 
by HPV infection annually, with greater than 273,000 deaths attributable to cervical cancer.
1  
Studies have shown that the first 5 years following sexual debut represents the period of highest 
risk for acquisition of HPV infection.
3
  An estimated annual cost for HPV related neoplasms in 
the year 2000 for ages 15-24 was $2.8 billion for women, and $62 million for men.
5
  In most 
countries the median/mean age of a primary sexual experience occurs between 15 and 16 years 
of age.
3
  Studies have also proved that oral HPV infection is a strong risk factor for 
oropharyngeal cancer.  Researchers found that an oral HPV infection and past HPV exposure  
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increase the risk of oropharyngeal of squamous cell cancer regardless of tobacco and alcohol 
use.
4
  Therefore it is important that the vaccine be extended to both male and female genders, 
offering HPV cancer prophylaxis and prevention to both sexes. Extending the vaccine to both 
males and females can help to decrease transmission of the HPV virus regardless of one’s gender 
or sexual preference. 
Gardisil is a quadrivalent 3 dose regimen vaccine that protects against HPV types 6, 11, 
16, and 18.  It has been proven to be highly protective and effective when given to females.  
Gardisil was FDA approved for the male gender in 2009, after studies showed proven 
effectiveness and immunogenicity in the male gender.  Another HPV vaccine on the market is 
under the name of Cervarix.  This is a bivalent vaccine offering protection against HPV types 16, 
and 18.  At this time Cervarix is only FDA approved and indicated for the female gender.  The 
highest risk of acquiring HPV infection is within the first 5 years after sexual debut, and because 
of this, the HPV prophylactic vaccination against would have the greatest benefit in sexually 
naïve adolescents.
3 
 The quadrivalent vaccine is however now approved and indicated for males 
and females 9-26 years of age, regardless of their sexual preference or number of sexual partners.   
Objective 
 The objective of this systematic review is to determine whether “It is safe and effective to 
vaccinate the male gender to prevent HPV related neoplastic disorders in both the male and 
female genders?”  Recent approval of Gardisil does indicate safety and efficacy in boys and men 
9 through 26 years of age for the prevention of genital warts (condyloma acuminata) caused by  
HPV types 6 and 11.  The FDA did not indicate the use of Gardisil in the male gender to help 
Diosdado “HPV Vaccine and Males” 3 
protect or prevent the transmission of HPV types 16, and 18.   
Methods 
A detailed search was completed by the author of this review using the advanced search 
engine of PubMed, Ovid, Cochrane database of Randomized Control Trials, and Cochrane 
database of Systematic Reviews.  Key words in this research search were:  Boys, Gardisil, HPV, 
and HPV Vaccine and Males.  This combination search was done and limits were placed for 
published articles written in the English language from the time period of 2000 to 2009.  The 
criteria used for the selection of studies focused on the male population ages 9 to 26.  
Administration of the HPV vaccine was the intervention; compared to those who received a 
placebo vaccine, or injection of saline.  Articles that were selected were based on Patient 
Oriented Evidence that Matters (POEM).  Outcomes were based upon the safety and tolerability 
of the vaccine as measured by the patient, and whether or not the vaccine would prevent the 
patient from having cancerous or neoplastic HPV (patient oriented evidence that matters).  
Clinically, titers were drawn to prove the level of immunogenicity that the males would retain by 
receiving the HPV vaccine, and also proving that males were non-inferior to females with 
immunogenicity to the quadrivalent or bivalent HPV vaccine.  The actual numeric value of the 
titer levels are not considered POEM based because the antibody response is not something that 
the patient cares about; however, it is the method clinically that researchers can use to prove 
immunogenic response.  Out of the three studies that were included; one was a comparative 
study and the other two were randomized controlled trials.  Two of the studies were double 
blinded and the third study was observer blinded.  The results of these demographics are 
displayed in Table 1 along with the description of inclusion and exclusion criteria for the  
individual studies.  All three studies focused on the safety and efficacy of either the bivalent or 
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quadrivalent vaccine within the male population. Table 1 
Study Type # of  
Pt’s 
Age in 
Years 
Inclusion  
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Block 
2006 
Comparative 
Study 
Randomized 
Double- 
Blinded 
1,529 10-15 
Male 
and 
female 
 
 
16-23 
Female 
Only 
Healthy boys 
and girls that 
were sexually 
naïve before 
and during the 
study.  For the 
older 
population of 
females only, 
they were 
required to be 
generally 
healthy, have 
an intact uterus, 
with no 
evidence of 
cervicitis.   
Allergy to any 
vaccine 
component; if 
they had recvd 
blood or 
components 
within the past 6 
mos.; had any 
known immune 
or coagulation 
disorder; had 
recvd any  
vaccine product 
within 14 days 
before 
enrollment or 
any live vaccine 
product 21 days 
before 
enrollment.  The 
older females 
aged 16-23 were 
excluded if they 
had HX of 
genital warts, 
abnormal pap, 
HX of CIN, or > 
4 lifetime sexual 
partners.  
2 Quadrivalent 
HPV vaccine 
6/11/16/18; 
this was 
administered 
to both male 
and female 
populations to 
compare 
immune 
response. 
Reisinger 
2007 
RCT 
Observer 
Blinded 
1,781 9-15 Healthy boys and 
girls that were 
sexually naïve 
going into the 
study. 
Similar to that 
described for a 
non-inferiority 
immunogenicity 
bridging study. 
3
  
6 Quadrivalent 
HPV vaccine 
6/11/16/18; vs. 
saline placebo. 
Petaja 
2009 
RCT 
Double-
Blinded 
270 10-18 Healthy boys. Use of an 
investigational 
drug or vaccine 
within 30 days; 
use of immune 
modifying drugs 
within 6 mos; 
blood or  
products within 3 
mos; previous 
vaccine of HBV 
or HPV; 
active/past HBV 
infection; HIV. 
8 HPV 16/18 
AS04-
adjuvanted 
vaccine vs. the 
HBV control 
vaccine. 
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Outcomes Measured 
All 3 studies maintained a congruent approach to measure the safety and tolerability of 
the vaccine.  The participants were observed for at least 30 minutes after each vaccination for 
any immediate reaction.  Oral temperatures were recorded for 5 days following each injection.  
The method that participants used to track their local or systemic adverse advents (AEs) is 
known as a vaccination report card (VRC).  Adult participants maintained a VRC themselves 
post vaccination; and the VRC for adolescent participants were tracked by their parent/guardian.  
Participants were given a scale and asked to rate their symptoms based upon mild, moderate, or 
severe.  “Mild” was defined as awareness of signs or symptoms, but easily tolerated; “moderate” 
was defined by discomfort enough to cause interference with usual activities; and “severe” was 
incapacitating with the inability to work or do usual activities (Block).
1  
The other outcome measured regarding a POEM based patient perspective is, do those 
patients now have the protection from receiving or transmitting HPV related neoplasms?  
Although the titer levels do show immunity, that is not something that a patient can gauge from 
his or her perspective.  However, the patient can gauge whether or not they have or can transmit 
cancerous growths to their anogenital region.   
 
Results: Tables 2-7 to include all three separate studies.   
Table 2 and Table 3 Study on Comparison of the immunogenicity and Reactogenicity of 
Prophylactic Quadrivalent HPV (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine in 
Male and Female Adolescents and Young Adult Women. 
 
 
 
 
 
 
Diosdado “HPV Vaccine and Males” 6 
Table 2: Safety Across all 3 series of vaccinations                         
 Girls Boys Women 
 n/% n/% n/% 
Participants 
follow-up 
501 500 497 
Vaccine  
AEs 
423/84.4 396/79.2 444/89.3 
Injection 
site AEs 
405/80.8 370/74.0 435/87.5 
Systemic 
AEs 
154/30.7 136/27.2 160/32.2 
Serious 
AEs 
1/0.2 1/0.2 0/0.0 
 
Table 3: Efficacy; Non-inferiority of GMTs in Girls and Boys Vs Women at Month 7 
 Girls Boys Women GMT Ratio 
 (95% CI) 
GMT Ratio 
 (95% CI) 
Assay 
(cLIA) 
n/GMT
a 
(mMU/ml) 
n/GMT
a 
(mMU/ml) 
n/GMT
a 
(mMU/ml) 
Girls/Women Boys/Women 
Anti- 
HPV6 
423/959 428/1042 320/575 1.67
b 
(1.46-
1.91) 
1.81
b
 (1.58-
2.08) 
Anti- 
HPV11 
423/1220 428/1318 320/706 1.73
b 
(1.50-
2.00) 
1.87
b 
(1.60-
2.17) 
Anti- 
HPV16 
424/4697 427/5638 306/2548 1.84
b 
(1.54-
2.20) 
2.21
b 
(1.84-
2.66) 
Anti- 
HPV18 
426/916 429/1212 340/453 2.02
b 
(1.71-
2.39) 
2.68
b 
(2.24-
3.19) 
a 
Based on a statistical model adjusting for region. 
b
Noninferiority P< .001 
Table 4 and Table 5 is the Immunogenicity and Safety of HPV 16/18 AS04-Adjuvanted Vaccine 
in Healthy Boys Aged 10-18 Years 
Table 4 Safety and Tolerability of the HPV vaccine vs. Placebo 
  HPV 16/18 
N=523 
 HBV  N=259 
Control 
 
Symptom Type n (%) (95% CI) n (%) (95% CI) 
Pain All 378 (72.3) (68.2, 76.1) 57 (22.0) (17.1, 27.6) 
 Grade3
a
 10 (1.9) (0.9, 3.5) 0 (0.0) (0.0, 1.4) 
Redness All 87 (16.6) (13.5, 20.1) 29 (11.2) (7.6, 15.7) 
 >50mm 0 (0.0) (0.0, 0.7) 0 (0.0) (0.0, 1.4) 
Swelling All 56 (10.7) (8.2, 13.7) 8 (3.1) (1.3, 6.0) 
 >50mm 2 (0.4) (0.0, 1.4) 1 (0.4) (0.0, 2.1) 
N= number of documented doses (with safety diary cards returned) 
CI= exact confidence interval; n (%) = number/percentage of doses that were followed by at least one symptom.  
a
 Pain that prevented normal activity. 
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Table 5 Immunogenicity Table
2; GMT’s for HPV 16 and 18 antibodies in initially 
seronegative boys aged 10 to 18 years at month 2 and month 7 
 
 
 
 
 
 
Table 6 and 7 study on the Safety and Persistent Immunogenicity of the Quadrivalent 
Vaccine in Preadolescents and Adolescents  
Table 6 Safety and Adverse Experience Summary Across all 3 series of vaccines 
 Vaccine Non-aluminum Placebo 
# of subjects w/ Follow-up 1165 584 
1 or more AE 963 (82.7) 392 (67.1) 
Injection-site AE 877 (75.3) 292 (50.0) 
Erythema 237 (20.3) 77 (13.2) 
Pain 853 (73.2) 265 (45.4) 
Swelling 241 (20.7) 45 (7.7) 
Systemic AE 541 (46.4) 260 (44.5) 
With serious AE 5 (0.4) 0 (0.0) 
Fever; total number affected 1157 579 
<100 degrees F or normal 1074 (92.8) 541 (93.4) 
≥100 degrees F 83 (7.2) 38 (6.6) 
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Table 7 Analysis of Month 7 Anti-HPV Responses for HPV Types 6/11/16/18 
Parameter Boys  Girls  Difference/Fold Difference  
(95% CI)* 
 n Response n Response  
Anti-HPV 6 
%Seroconversion 
456 99.8 492 99.8 0.0 (-1.0, 1.0) 
 
GMT 
(mMU/mL) 
 1007  808 1.3 (1.0, 1.5) 
Anti-HPV 11 
%Seroconversion 
457 99.8 492 99.8 0.0 (-1.0, 1.0) 
 
GMT 
(mMU/mL) 
 1334  1187 1.1 (0.9, 1.4) 
Anti-HPV 16 
%Seroconversion 
455 99.5 489 99.8 -0.2 (-1.4, 0.8) 
GMT 
(mMU/mL) 
 6316  4490 1.4 (1.1, 1.8) 
Anti-HPV 18 
%Seroconversion 
458 99.8 494 99.6 0.2 (-0.8, 1.3) 
GMT 
(mMU/mL) 
 1581  1071 1.5 (1.2, 1.9) 
*Difference = Boys minus girls; Fold difference = boys divided by girls.  P < 0.001 for all tests 
of noninferiority of immune response in boys to those in girls (for all 4 vaccine HPV types for 
both endpoints).   
 
Results 
The main point out of these three studies is to hypothesize whether or not it is safe and 
effective to vaccinate the male gender with a HPV vaccine.  In Table 2 and Table 3, the Block 
study shows a comparison of immune response as well as safety of the vaccine in adolescents as 
compared to women ages 16-23.  The table provided includes all of the three groups of 
participants and averages the outcome of tolerability and safety.  The 3 dose regimen of the HPV 
vaccine was overall well tolerated.  The most commonly reported systemic adverse events were 
headache (23.2%) and fever (13.1%).
1 
 The majority of the injection site reactions  
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were mild to moderate, characterized by redness and swelling.  The first dose of the three dose 
regimen was reported to carry the most complaints for redness and swelling.  There were three 
serious adverse events, 2 of them were proved to be unrelated to the vaccine; a cardiac 
ventricular arrhythmia, and the second serious AE was an intentional overdose on 
chlorpheniramine tablets and homeopathic arsenicum.  The third serious AE was deemed to be 
vaccine related by the reporting Physician; this participant was a 13 year old girl affected with a 
vaginal hemorrhage 26 days post-dose 2 of the HPV vaccine.  
Table 3 shows that the male population was non-inferior to immunogenicity of the girls 
and woman at the 7
th
 month; titers drawn 4 weeks after the 3
rd
 dose of the vaccination regimen.  
The end points of the study were the geometric mean titers (GMTs) of neutralizing antibodies for 
each HPV type.
1
  The sample size of the study was chosen to provide >99% power to declare 
noninferiority in immunogenic responses and seroconversion rates for at least 1 of the 
populations (girls or boys compared with women) (Block).
1
  Therefore, turning this data into 
POEM data, males are just as protected as females are from HPV after receiving the HPV 
vaccine.  
Table 4, Table 5, Table 6, and Table 7 show the same type of information as described in 
Table 2 and Table 3.  Table 4 does show that there were more AE’s of local and systemic 
reactions with the HPV and compared to the placebo HBV vaccine.  The Petaja study does 
mention however that the solicited local symptoms did not affect compliance with the 
vaccination, as evidenced by 97% of the boys in both vaccine groups completed the three dose 
vaccination course.
2
  As shown in Table 5, the immune response in boys aged 10 to 18 years in 
this study was noninferior for both seroconversion rates and GMTs to that seen in women aged 
15 to 25 years in the historic comparator study, an age range in which a high  
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degree of protection against HPV 16/18 infection and associated cervical lesions has been shown 
(Petaja).
2
  Again, POEM based data is that males are as protected as females after receiving the 
vaccine.  
Tables 6 and 7 are much like that of the study of Tables 2 and 3.  It is mentioned in the study 
that 5 serious adverse events were reported through month 18, all of which occurred among the 
quadrivalent HPV vaccine recipients, and were judged by the investigator to be not vaccine 
related.  As in the previous study, infection site adverse experiences were greater than placebo 
but few participants discontinued the vaccination series because of the AEs.  Table 7 shows that 
for each of the 4 vaccine types, ≥99.5% of the subjects in the respective per-protocol 
immunogenicity cohort had seroconverted by 1 month after completion of the 3-dose regimen, 
regardless of their gender (Reisinger).
3
   
Discussion 
 The two RCTs and one comparative study showed overall that the quadrivalent and the 
bivalent HPV vaccine was safe and effective in preventing HPV and HPV related neoplasms.  
There were adverse events that occurred within the HPV population greater than that within the 
placebo, however, most of the events were consistent with local injection site redness and 
soreness, and systemic reactions of either headache or fever.  Most of these adverse events were 
tolerated and discontinuance due to AEs of the vaccine regimen was a rarity.  Immunogenicity of 
the said HPV strains was proved by titer levels.   
Conclusion  
 The antibody response of the HPV vaccine was shown to be noninferior to the studies 
done in girls and women.  The HPV vaccine was also proved to be overall safe with few minor  
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immediate local and systemic side effects.  Statistically, studies have shown that the first 5 years 
following sexual debut represents the period of highest risk for acquisition of HPV infection.
3
  
Therefore, immunizing males and females before their sexual debut becomes important to 
prevent receiving and transmitting HPV.  Thus stating, the vaccine should be targeted towards 
adolescents and preteens.  As mentioned in the introduction, an estimated annual cost for HPV 
related neoplasms in the year 2000 for ages 15-24 was $2.8 billion for women, and $62 million 
for men.
5
  It can only be assumed that in the year 2010, the incidence has increased.  Given those 
statistics, it is clear that HPV affects and takes lives of many individuals.  HPV infection is 
common in men and is readily transmitted influencing disease rates in both men and woman 
(Petaja).
2
  The findings of safety and immunogenicity of the HPV vaccine in the male population 
definitely lend support to the implementation of a gender neutral vaccine to prevent widespread 
morbidity and mortality from HPV related cancers, as well as dysplastic cervical and external 
genital lesions affecting the general population.  The limitations to this study include long term 
immune response which would necessitate the need for a booster vaccine.    
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